Research and Markets has announced the addition of the "Pneumococcal Infections Pipeline Highlights - 2017" drug pipelines to their offering.

This report, Pneumococcal Infections Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Pneumococcal Infections market. It covers emerging therapies for Pneumococcal Infections in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Pneumococcal Infections pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Pneumococcal Infections pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Pneumococcal Infections pipeline products by the company.

Short-term Launch Highlights:

Find out which Pneumococcal Infections pipeline products will be launched in the US and Ex-US till 2020.

Summary:

  • Pneumococcal Infections phase 3 clinical trial pipeline products
  • Pneumococcal Infections phase 2 clinical trial pipeline products
  • Pneumococcal Infections phase 1 clinical trial pipeline products
  • Pneumococcal Infections preclinical research pipeline products
  • Pneumococcal Infections discovery stage pipeline products
  • Pneumococcal Infections pipeline products short-term launch highlights

Key Topics Covered:

1. Pneumococcal Infections Pipeline by Stages

2. Pneumococcal Infections Pipeline by Drug Class

3. Pneumococcal Infections Pipeline by Company

4. Pneumococcal Infections Phase 3 Clinical Trial Insights

5. Pneumococcal Infections Phase 2 Clinical Trial Insights

6. Pneumococcal Infections Phase 1 Clinical Trial Insights

7. Pneumococcal Infections Preclinical Research Insights

8. Pneumococcal Infections Discovery Stage Insights

9. Appendix

10. Research Methodology

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/5v3g3x/pneumococcal